OBJECTIVES: To evaluate Phramongkutklao CPG for treatment of neonatal infection in newborn infants with maternal history of PROM for ≥18 hours and the impact on saving hospital cost. METHODS: Prospective cohort study. Infants with maternal history of PROM were categorized into 1 of 3 groups: group I, having symptoms within 6 hours after birth; group II, having history of maternal chorioamnionitis and group III, healthy infants without history of maternal chorioamnionitis. All infants in group I and II were treated with antibiotics. Infants in group III were ranked by using PROM scoring system. The success of CPG was defined as no re-admission due to infection occurred within 28 days of age. Logistic regression was used to determine the association between neonatal infection and risk factors. RESULTS: In total, 109 of 5182 (2.10%) infants born during study period had maternal history of PROM, 5 cases were excluded. Twenty-nine of 104 (27.88%) infants had infection and were treated with antibiotics. The CPG successfully identified different risk of infection in 102 of 104 (98.08%) infants. The use of CPG reduced a number of infants treated with antibiotics from 81 to 38 (53.09%) compared to the previous strategies. The relative risk of 1-minute Apgar scores £5, duration of PROM >72 hours, gestational age <34 wk, birth weight 1500-2500 g and birth weight <1500 g were 3.82 (95%CI 2.43-5.99), 3.47 (95%CI 1.56-7.72), 5.33 (95%CI 2.77-10.25), 3.40 (95%CI 1.84-6.28) and 6.17 ( 95%CI 3.67-10.35), respectively. Logistic regression analysis equation was log [Infection Rate] = 4.148 -3.028 [gestational age <34 wk] -2.444 [gestation age 34-37 wk] -3.029 [1-minute Apgar score] (R 2 = 0.84). Using CPG reduced expenditure for treatment from 469,395 Baht to 237,700 Baht or 139,017 Baht per year. CONCLUSIONS: Phramongkutklao CPG on PROM is safe and cost saving for managing newborn infants at risk.
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Städt. Klinikum St. Georg, Leipzig, Germany; 2 MEDTAP International Inc, London, UK; 3 MEDTAP International Inc, Bethesda, MD, USA; 4 Pfizer GmBH, Karlsuhe, Germany; 5 Pfizer Inc, New York, NY, USA OBJECTIVES: Linezolid, a novel antibiotic, has demonstrated efficacy in known or suspected methicillin-resistant Staphylococcus aureus (MRSA) infections. Among patients with MRSA nosocomial pneumonia, survival and clinical cure rates (resolution of baseline signs and symptoms) were better for those treated with linezolid versus vancomycin: 80% versus 63.5% (survival) and 59% versus 35.5% (clinical cure) (Chest. 2003; 124:1789-97) . We evaluated the economic impact of these clinical outcomes from the German perspective. METHODS: A decision-analytic model was developed to examine the costs and outcomes of using linezolid versus vancomycin in hospitalized patients with nosocomial pneumonia in a German setting. Five German physicians experienced in treating nosocomial pneumonia provided resource utilization data through structured interviews. Costs from published sources (Rote Liste, EBM, DKG-NT) were applied to tests, adverse events, isolation and days of intravenous and oral (linezolid only) treatment and hospitalization by ward type (medical, intensive-care). The model assumed 50% of suspected MRSA patients had proven MRSA. Outcomes included total costs per patient, cost per death avoided, cost per life-year gained and cost per cure. RESULTS: An additional 11% of patients treated with linezolid (71%) versus vancomycin (60%) were cured. Average total cost per episode was 12,288€ versus 11,444€ for linezolid-versus vancomycin-treated patients, translating to €7756 per additional patient cured. Death rates were 21% (linezolid) versus 34% (vancomycin), resulting in an average 2.3 life-years gained per linezolid patient in a 65-year-old cohort (13.6 versus 11.3 years). Using incremental costs from the treatment episode, the costs per life-year gained and death avoided were 371€ and 5124€, respectively. Although the model was sensitive to the percentage of proven MRSA cases and costs accrued by patients who die, varying these parameters by 25% did not change the overall conclusions. CONCLUSIONS: Linezolid is cost-effective versus vancomycin in the treatment of nosocomial pneumonia due to suspected MRSA.
PIN3 LINEZOLID FOR THE TREATMENT OF SKIN AND SOFT-TISSUE MRSA INFECTIONS-A COST-EFFECTIVE ALTERNATIVE TO VANCOMYCIN: EVIDENCE FROM A MULTINATIONAL CLINICAL TRIAL
Sorensen SV 1 , Hollenbeak CS 1 , Baker TM 1 , Resch A 2 , Duttagupta S 3 1 MEDTAP International Inc, Bethesda, MD, USA; 2 Pfizer GmBH, Karlsruhe, Germany; 3 Pfizer Inc, New York, NY, USA OBJECTIVES: A recent multi-country clinical trial of complicated skin and soft-tissue infections (cSSTI) due to proven or suspected methicillin-resistant Staphylococcus aureus (MRSA) demonstrated superior efficacy with linezolid compared with vancomycin. In this study, we estimated whether treatment with linezolid was also cost-effective versus vancomycin in patients with cSSTI. METHODS: All 1180 patients from the clinical trial (592 linezolid, 588 vancomycin) admitted to hospitals in 16 countries with cSSTI due to suspected or proven MRSA were studied. Costs of hospitalization for each patient were estimated by applying country-specific 2003 per diem hospital costs for days in the medical/surgical, intensive care, or the step-down units. Costs of intravenous (IV) therapy were applied to the duration of IV treatment plus administration costs. Medications were valued at wholesale acquisition cost. Medical resource costs from available countries were used before converting to US dollars using purchasing power parity adjustments. Furthermore, both costs and outcomes were risk adjusted using multivariate methods to account for patient population differences between countries. The cost effectiveness was measured as incremental cost per additional patient cured. RESULTS: There were no significant differences at baseline in clinical and demographic characteristics between the linezolid and vancomycin groups. Average risk-adjusted cost for patients treated with linezolid was $3629 versus $4140 (P < 0.0001) for patients treated with vancomycin. In addition, the predicted cure rate for the linezolid
